Claritas Genomics
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Series A | ||
$15.0m | Series B | ||
Total Funding | AUD23.2m |
Recent News about Claritas Genomics
EditClaritas Genomics is a genetic diagnostic laboratory specializing in pediatric disorders. Originating from the in-house genetic testing lab at Boston Hospital, Claritas was launched as a standalone entity in February 2013. The company serves healthcare providers, particularly pediatric hospitals, by offering comprehensive genetic testing services. Claritas operates in the genomics market, focusing on providing accurate and timely diagnostic information to improve patient care. The business model revolves around offering a range of genetic tests, including the Pediatric Neurology Exome and the Nephrotic Syndrome Panel, which are designed to diagnose complex pediatric conditions. Revenue is generated through the sale of these diagnostic tests and associated services, such as clinical reporting and expert consultations. The company also engages in research services, offering Ion Exome Sequencing to researchers. Claritas is committed to advancing the field of genomics through educational resources and partnerships with healthcare providers.
Keywords: genetic diagnostics, pediatric disorders, genomics, exome sequencing, clinical testing, pediatric hospitals, diagnostic services, healthcare providers, genetic testing, research services.